Publications by authors named "Walter Singleton"

Claim this Profile
V
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Seth J Baum, Eunju Hurh, Joyce Kingsbury, Walter Singleton

Eur Heart J· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
Andres Digenio, Richard L Dunbar, Veronica J Alexander, Marcus Hompesch, Linda Morrow, Walter Singleton

Diabetes Care· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects.
Rosie Z Yu, Rudy Gunawan, Zhaoyang Li, Robert S Mittleman, Asif Mahmood, Walter Singleton

Eur J Clin Pharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Sotirios Tsimikas, Nicholas J Viney, Steven G Hughes, Walter Singleton, Mark J Graham

Lancet· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
Daniel Gaudet, Veronica J Alexander, Brenda F Baker, Diane Brisson, Karine Tremblay, Walter Singleton

N Engl J Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.
Marshelle S Warren, Steven G Hughes, Walter Singleton, Mason Yamashita, Mark C Genovese

Arthritis Res Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting APOC3 in the familial chylomicronemia syndrome.
Daniel Gaudet, Diane Brisson, Karine Tremblay, Veronica J Alexander, Walter Singleton

N Engl J Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Mark J Graham, Richard G Lee, Thomas A Bell, Wuxia Fu, Adam E Mullick, Walter Singleton

Circ Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans.
Nicholas R Jones, Melissa A Pegues, Mark A McCrory, Walter Singleton, Claudette Bethune

Mol Ther Nucleic Acids· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial.
Carlos A Molina, Andrew D Barreto, Georgios Tsivgoulis, Paul Sierzenski, Marc D Malkoff, Walter Singleton

Ann Neurol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis